Last reviewed · How we verify
NCT04257513: Chol-HD
Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HD
trial testing Brain MRI in Huntington Disease in 60 participants. Completed in 2 June 2023.
6 March 2023
Quick facts
| Lead sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 31 October 2019 |
| Primary completion | 6 March 2023 |
| Estimated completion | 2 June 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Brain MRI — full drug profile →
Conditions studied
- Huntington Disease — all drugs for Huntington Disease →
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — full company profile →
Who can join
18 and older, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A 2-year clinical longitudinal study to measure plasma concentrations of 24S-hydroxycholesterol, a brain-derived cholesterol catabolite, in subjects with Huntington disease, from the presymptomatic to the symptomatic stages.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04257513
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Brain MRI
Trials testing the same drug.
- NCT07462507 — Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 · Phase 2 · not yet recruiting
- NCT07340736 — Sensory Mechanisms of Manual Dexterity Recovery After Stroke: a Prospective Cohort Study of Prediction and Cerebral Corr · NA · not yet recruiting
- NCT06865677 — Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas · Phase 2 · terminated
- NCT06461065 — Evaluation of Neurodevelopmental Trajectories in Children According to the Glycemic Profile Associated With Different Ea · NA · recruiting
- NCT04796714 — AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE · Phase 4 · unknown
Other recruiting trials for Huntington Disease
Currently open trials in the same condition.
- NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
- NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
- NCT06774443 — Hinting Task for Huntington's Disease · recruiting
- NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
- NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting
Other Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials
Trials by the same sponsor.
- NCT07168850 — Focused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia · NA · recruiting
- NCT06699095 — Home Rehabilitation As Continuity of Care in MS · NA · recruiting
- NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
- NCT06584097 — COMparative Performance of General Purpose Models · recruiting
- NCT07427940 — Omic Profile in Autism Spectrum Disorder: From Cellular Level Towards Future Treatments · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04257513 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Last refreshed: 12 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04257513.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing